Cell penetrating peptides for tumor targeting

Current Pharmaceutical Biotechnology

Volumn 12, Issue 8, 2011, Pages 1166-1182

  Choi, Young Suk ^a   Lee, Jue Yeon ^d   Suh, Jin Sook ^a   Lee, Seung Jin ^c   Yang, Victor C ^b   Chung, Chong Pyoung ^a   Park, Yoon Jeong ^a  

^a BK 21 Plus   (South Korea)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Ewha Womans University   (South Korea)

^d NanoIntellegent Biomedical Engineering Corporation (NIBEC)   (South Korea)

Author keywords

Antitumor drug delivery; Cell penetrating peptides (cpp); Intracellular drug delivery; Molecular cargo

Indexed keywords

ALPHA INTERFERON; ANTENNAPEDIA PROTEIN; ARGININE; CAMPTOTHECIN; CELL PENETRATING PEPTIDE; DRUG CARRIER; GELONIN; GLYCOPROTEIN P; INTERLEUKIN 12; LIPOSOME; LOW MOLECULAR WEIGHT PROTAMINE; NANOPARTICLE; OCTAMER TRANSCRIPTION FACTOR; PENETRATIN; PEPTIDE DERIVATIVE; PLASMID DNA; POLYARGININE; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P53; PROTEIN VP22; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; TRANSPORTAN 10; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRACELLULAR SPACE; MACROMOLECULE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; ANIMALS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS;

EID: 79959925211     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111796117391     Document Type: Article

References (145)

1. Syrigos, K.N.; Epenetos, A.A. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res., 1999, 19(1A), 605-613.
2. Liang, J.F.; Li, Y.T.; Song, H.; Park, Y.J.; Naik, S.S.; Yang, V.C. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs. J. Control Release, 2002, 78(1-3), 67-79.
3. Chari, R.V. Targeted delivery of chemotherapeutics: tumoractivated prodrug therapy. Adv. Drug Deliv. Rev., 1998, 31(1-2), 89-104.
4. Mellman, I. Endocytosis and molecular sorting. Annu. Rev. Cell Dev. Biol., 1996, 12, 575-625.
5. Niesner, U.; Halin, C.; Lozzi, L.; Gunthert, M.; Neri, P.; Wunderli- Allenspach, H.; Zardi, L.; Neri, D. Quantitation of the tumortargeting properties of antibody fragments conjugated to cellpermeating HIV-1 TAT peptides. Bioconjug Chem., 2002, 13(4), 729-736.
6. Fawell, S.; Seery, J.; Daikh, Y.; Moore, C.; Chen, L.L.; Pepinsky, B.; Barsoum, J. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U S A., 1994, 91(2), 664-668.
7. Fonseca, S.B.; Pereira, M.P.; Kelley, S.O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev., 2009, 61(11), 953-964.
8. Kerkis, A.; Hayashi, M.A.; Yamane, T.; Kerkis, I. Properties of cell penetrating peptides (CPPs). IUBMB Life, 2006, 58(1), 7-13.
9. Frankel, A.D.; Pabo, C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988, 55(6), 1189-1193.
10. Green, M.; Loewenstein, P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell, 1988, 55(6), 1179-1188.
11. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem., 1997, 272(25), 16010-16017.
12. Joliot, A.; Pernelle, C.; Deagostini-Bazin, H.; Prochiantz, A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad Sci. USA, 1991, 88(5), 1864-1868.
13. Derossi, D.; Joliot, A.H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem., 1994, 269(14), 10444-10450.
14. Elliott, G.; O'Hare, P., Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell, 1997, 88(2), 223-233.
15. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y., Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem., 2001, 276(8), 5836-5840.
16. Rosenbluh, J.; Singh, S.K.; Gafni, Y.; Graessmann, A.; Loyter, A., Non-endocytic penetration of core histones into petunia protoplasts and cultured cells: a novel mechanism for the introduction of macromolecules into plant cells. Biochim. Biophys. Acta., 2004, 1664(2), 230-240.
17. Rosenbluh, J.; Hariton-Gazal, E.; Dagan, A.; Rottem, S.; Graessmann, A.; Loyter, A., Translocation of histone proteinsacross lipid bilayers and Mycoplasma membranes. J. Mol. Biol., 2005, 345(2), 387-400.
18. Mitchell, D.J.; Kim, D.T.; Steinman, L.; Fathman, C.G.; Rothbard, J.B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res., 2000, 56(5), 318-325.
19. Suzuki, T.; Futaki, S.; Niwa, M.; Tanaka, S.; Ueda, K.; Sugiura, Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem., 2002, 277(4), 2437-2443.
20. Futaki, S.; Nakase, I.; Suzuki, T.; Youjun, Z.; Sugiura, Y. Translocation of branched-chain arginine peptides through cell membranes: flexibility in the spatial disposition of positive charges in membrane-permeable peptides. Biochemistry, 2002, 41(25), 7925-7930.
21. Chang, L.C.; Lee, H.F.; Yang, Z.; Yang, V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. AAPS PharmSci., 2001, 3(3), E17.
22. Chang, L.C.; Liang, J.F.; Lee, H.F.; Lee, L.M.; Yang, V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity. AAPS PharmSci., 2001, 3(3), E18.
23. Lee, L.M.; Chang, L.C.; Wrobleski, S.; Wakefield, T.W.; Yang, V.C. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci., 2001, 3(3), E19.
24. Pooga, M.; Hallbrink, M.; Zorko, M.; Langel, U. Cell penetration by transportan. FASEB J., 1998, 12(1), 67-77.
25. Chiu, Y.L.; Ali, A.; Chu, C.Y.; Cao, H.; Rana, T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol., 2004, 11(8), 1165-1175.
26. Rothbard, J.B.; Garlington, S.; Lin, Q.; Kirschberg, T.; Kreider, E.; McGrane, P.L.; Wender, P.A.; Khavari, P.A., Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med., 2000, 6(11), 1253-1257.
27. Santra, S.; Yang, H.; Stanley, J.T.; Holloway, P.H.; Moudgil, B.M.; Walter, G.; Mericle, R.A., Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem. Commun. (Camb), 2005(25), 3144-3146.
28. Lewin, M.; Carlesso, N.; Tung, C.H.; Tang, X.W.; Cory, D.; Scadden, D.T.; Weissleder, R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol., 2000, 18(4), 410-414.
29. Nagahara, H.; Vocero-Akbani, A.M.; Snyder, E.L.; Ho, A.; Latham, D.G.; Lissy, N.A.; Becker-Hapak, M.; Ezhevsky, S.A.; Dowdy, S.F. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med., 1998, 4(12), 1449-1452.
30. Vives, E.; Schmidt, J.; Pelegrin, A. Cell-penetrating and celltargeting peptides in drug delivery. Biochim. Biophys. Acta, 2008, 1786(2), 126-138.
31. Heitz, F.; Morris, M.C.; Divita, G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol., 2009, 157(2), 195-206.
32. Frankel, A.D.; Bredt, D.S.; Pabo, C.O. Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science, 1988, 240(4848), 70-73.
33. Frankel, A.D.; Chen, L.; Cotter, R.J.; Pabo, C.O. Dimerization of the tat protein from human immunodeficiency virus: a cysteine-rich peptide mimics the normal metal-linked dimer interface. Proc. Natl. Acad. Sci. U S A., 1988, 85(17), 6297-6300.
34. Ruben, S.; Perkins, A.; Purcell, R.; Joung, K.; Sia, R.; Burghoff, R.; Haseltine, W.A.; Rosen, C.A. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol., 1989, 63(1), 1-8.
35. Siomi, H.; Shida, H.; Maki, M.; Hatanaka, M. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J. Virol., 1990, 64(4), 1803-1807.
36. Weeks, K.M.; Ampe, C.; Schultz, S.C.; Steitz, T.A.; Crothers, D.M. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science, 1990, 249(4974), 1281-1285.
37. Loret, E.P.; Vives, E.; Ho, P.S.; Rochat, H.; Van Rietschoten, J.; Johnson, W.C., Jr. Activating region of HIV-1 Tat protein: vacuum UV circular dichroism and energy minimization. Biochemistry, 1991, 30(24), 6013-6023.
38. Schwarze, S.R.; Hruska, K.A.; Dowdy, S.F., Protein transduction: unrestricted delivery into all cells? Trends Cell Biol., 2000, 10(7), 290-295.
39. Gehring, W.J.; Affolter, M.; Burglin, T., Homeodomain proteins. Annu. Rev. Biochem., 1994, 63, 487-526.
40. Derossi, D.; Calvet, S.; Trembleau, A.; Brunissen, A.; Chassaing, G.; Prochiantz, A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem., 1996, 271(30), 18188-18193.
41. Han, K.; Jeon, M.J.; Kim, K.A.; Park, J.; Choi, S.Y., Efficient intracellular delivery of GFP by homeodomains of Drosophila Fushi-tarazu and Engrailed proteins. Mol. Cells, 2000, 10(6), 728-732.
42. Joliot, A.H.; Triller, A.; Volovitch, M.; Pernelle, C.; Prochiantz, A., alpha-2,8-Polysialic acid is the neuronal surface receptor of antennapedia homeobox peptide. New Biol., 1991, 3(11), 1121-1134.
43. Elliott, G.; O'Hare, P., Intercellular trafficking of VP22-GFP fusion proteins. Gene. Ther., 1999, 6(1), 149-151.
44. Aints, A.; Guven, H.; Gahrton, G.; Smith, C.I.; Dilber, M.S. Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting. Gene. Ther., 2001, 8(14), 1051-1056.
45. Pooga, M.; Soomets, U.; Hallbrink, M.; Valkna, A.; Saar, K.; Rezaei, K.; Kahl, U.; Hao, J.X.; Xu, X.J.; Wiesenfeld-Hallin, Z.; Hokfelt, T.; Bartfai, T.; Langel, U. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol., 1998, 16(9), 857-861.
46. Soomets, U.; Lindgren, M.; Gallet, X.; Hallbrink, M.; Elmquist, A.; Balaspiri, L.; Zorko, M.; Pooga, M.; Brasseur, R.; Langel, U., Deletion analogues of transportan. Biochim. Biophys. Acta., 2000, 1467(1), 165-176.
47. Morris, M.C.; Vidal, P.; Chaloin, L.; Heitz, F.; Divita, G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res., 1997, 25(14), 2730-2736.
48. Morris, M.C.; Depollier, J.; Mery, J.; Heitz, F.; Divita, G., A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol., 2001, 19(12), 1173-1176.
49. Morris, M.C.; Deshayes, S.; Heitz, F.; Divita, G. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol. Cell, 2008, 100(4), 201-217.
50. Deshayes, S.; Morris, M.; Heitz, F.; Divita, G. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv. Drug Deliv. Rev, 2008, 60(4-5), 537-547.
51. Wender, P.A.; Mitchell, D.J.; Pattabiraman, K.; Pelkey, E.T.; Steinman, L.; Rothbard, J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U S A., 2000, 97(24), 13003-13008.
52. Futaki, S.; Goto, S.; Sugiura, Y. Membrane permeability commonly shared among arginine-rich peptides. J. Mol. Recognit., 2003, 16(5), 260-264.
53. Morishita, M.; Kamei, N.; Ehara, J.; Isowa, K.; Takayama, K. A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control Release, 2007, 118(2), 177-184.
54. Byun, Y.; Singh, V.K.; Yang, V.C. Low molecular weight protamine: a potential nontoxic heparin antagonist. Thromb. Res, 1999, 94(1), 53-61.
55. Park, Y.J.; Chang, L.C.; Liang, J.F.; Moon, C.; Chung, C.P.; Yang, V.C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J., 2005, 19(11), 1555-1557.
56. Tung, C.H.; Mueller, S.; Weissleder, R., Novel branching membrane translocational peptide as gene delivery vector. Bioorg. Med. Chem., 2002, 10(11), 3609-3614.
57. Tsui, B.; Singh, V.K.; Liang, J.F.; Yang, V.C. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. Thromb. Res., 2001, 101(5), 417-420.
58. Liang, J.F.; Zhen, L.; Chang, L.C.; Yang, V.C. A less toxic heparin antagonist--low molecular weight protamine. Biochemistry (Mosc.), 2003, 68(1), 116-120.
59. Choi, Y.S.; Lee, J.Y.; Suh, J.S.; Kwon, Y.M.; Lee, S.J.; Chung, J.K.; Lee, D.S.; Yang, V.C.; Chung, C.P.; Park, Y.J. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials, 2009.
60. Said Hassane, F.; Saleh, A.F.; Abes, R.; Gait, M.J.; Lebleu, B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol. Life Sci., 2010, 67(5), 715-726.
61. Dietz, G.P.; Bahr, M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci., 2004, 27(2), 85-131.
62. Futaki, S. Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int. J. Pharm., 2002, 245(1-2), 1-7.
63. Thoren, P.E.; Persson, D.; Esbjorner, E.K.; Goksor, M.; Lincoln, P.; Norden, B. Membrane binding and translocation of cellpenetrating peptides. Biochemistry, 2004, 43(12), 3471-3489.
64. Thoren, P.E.; Persson, D.; Lincoln, P.; Norden, B. Membrane destabilizing properties of cell-penetrating peptides. Biophys. Chem., 2005, 114(2-3), 169-179.
65. Torchilin, V.P.; Rammohan, R.; Weissig, V.; Levchenko, T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad Sci. U S A., 2001, 98(15), 8786-8791.
66. Vives, E., Cellular uptake [correction of utake] of the Tat peptide: an endocytosis mechanism following ionic interactions. J. Mol. Recognit., 2003, 16(5), 265-271.
67. Richard, J.P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M.J.; Chernomordik, L.V.; Lebleu, B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem., 2003, 278(1), 585-590.
68. Vives, E.; Richard, J.P.; Rispal, C.; Lebleu, B. TAT peptide internalization: seeking the mechanism of entry. Curr. Protein. Pept. Sci., 2003, 4(2), 125-132.
69. Brooks, H.; Lebleu, B.; Vives, E. Tat peptide-mediated cellular delivery: back to basics. Adv. Drug Deliv. Rev., 2005, 57(4), 559-577.
70. Nakase, I.; Tadokoro, A.; Kawabata, N.; Takeuchi, T.; Katoh, H.; Hiramoto, K.; Negishi, M.; Nomizu, M.; Sugiura, Y.; Futaki, S. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry, 2007, 46(2), 492-501.
71. Fittipaldi, A.; Ferrari, A.; Zoppe, M.; Arcangeli, C.; Pellegrini, V.; Beltram, F.; Giacca, M. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem., 2003, 278(36), 34141-34149.
72. Kaplan, I.M.; Wadia, J.S.; Dowdy, S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control Release, 2005, 102(1), 247-253.
73. Nakase, I.; Niwa, M.; Takeuchi, T.; Sonomura, K.; Kawabata, N.; Koike, Y.; Takehashi, M.; Tanaka, S.; Ueda, K.; Simpson, J.C.; Jones, A.T.; Sugiura, Y.; Futaki, S. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther., 2004, 10(6), 1011-1022.
74. Richard, J.P.; Melikov, K.; Brooks, H.; Prevot, P.; Lebleu, B.; Chernomordik, L.V. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem., 2005, 280(15), 15300-15306.
75. Vandenbroucke, R.E.; De Smedt, S.C.; Demeester, J.; Sanders, N.N. Cellular entry pathway and gene transfer capacity of TATmodified lipoplexes. Biochim. Biophys. Acta, 2007, 1768(3), 571-579.
76. Fischer, R.; Kohler, K.; Fotin-Mleczek, M.; Brock, R. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem., 2004, 279(13), 12625-12635.
77. Duchardt, F.; Fotin-Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R. A comprehensive model for the cellular uptake of cationic cellpenetrating peptides. Traffic, 2007, 8(7), 848-866.
78. Dupont, E.; Prochiantz, A.; Joliot, A. Identification of a signal peptide for unconventional secretion. J. Biol. Chem., 2007, 282(12), 8994-9000.
79. Tunnemann, G.; Martin, R.M.; Haupt, S.; Patsch, C.; Edenhofer, F.; Cardoso, M.C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J., 2006, 20(11), 1775-1784.
80. Watkins, C.L.; Schmaljohann, D.; Futaki, S.; Jones, A.T., Low concentration thresholds of plasma membranes for rapid energyindependent translocation of a cell-penetrating peptide. Biochem. J., 2009, 420(2), 179-189.
81. Mueller, J.; Kretzschmar, I.; Volkmer, R.; Boisguerin, P., Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug Chem., 2008, 19(12), 2363-2374.
82. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H.K.; Gesson, J.P.; Koch, M.; Monneret, C., Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res., 1998, 58(6), 1195-1201.
83. Jain, R.K. Haemodynamic and transport barriers to the treatment of solid tumours. Int. J. Radiat Biol., 1991, 60(1-2), 85-100.
84. Jain, R.K.; Baxter, L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res., 1988, 48(24 Pt 1), 7022-7032.
85. Schwarze, S.R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999, 285(5433), 1569-1572.
86. Jo, D.; Nashabi, A.; Doxsee, C.; Lin, Q.; Unutmaz, D.; Chen, J.; Ruley, H.E. Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase. Nat. Biotechnol., 2001, 19(10), 929-933.
87. Xia, H.; Mao, Q.; Davidson, B.L., The HIV Tat protein transduction domain improves the biodistribution of betaglucuronidase expressed from recombinant viral vectors. Nat. Biotechnol., 2001, 19(7), 640-644.
88. Wadia, J.S.; Dowdy, S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev., 2005, 57(4), 579-596.
89. Tan, M.; Lan, K.H.; Yao, J.; Lu, C.H.; Sun, M.; Neal, C.L.; Lu, J.; Yu, D. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res., 2006, 66(7), 3764-3772.
90. Johansson, H.J.; El-Andaloussi, S.; Holm, T.; Mae, M.; Janes, J.; Maimets, T.; Langel, U. Characterization of a novel cytotoxic cellpenetrating peptide derived from p14ARF protein. Mol. Ther., 2008, 16(1), 115-123.
91. Begam, M.; Kumar, S.; Roy, S.; Campanella, J.J.; Kapoor, H.C. Molecular cloning and functional identification of a ribosome inactivating/antiviral protein from leaves of post-flowering stage of Celosia cristata and its expression in E. coli. Phytochemistry, 2006, 67(22), 2441-2449.
92. Barbieri, L.; Valbonesi, P.; Bonora, E.; Gorini, P.; Bolognesi, A.; Stirpe, F. Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A). Nucleic Acids Res., 1997, 25(3), 518-522.
93. Krawetz, J.E.; Boston, R.S. Substrate specificity of a maize ribosome-inactivating protein differs across diverse taxa. Eur. J. Biochem., 2000, 267(7), 1966-1974.
94. Goldmacher, V.S.; Tinnel, N.L.; Nelson, B.C. Evidence that pinocytosis in lymphoid cells has a low capacity. J. Cell Biol., 1986, 102(4), 1312-1319.
95. Harada, H.; Kizaka-Kondoh, S.; Hiraoka, M. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer, 2006, 13(1), 16-26.
96. Sherr, C.J.; McCormick, F. The RB and p53 pathways in cancer. Cancer Cell, 2002, 2(2), 103-112.
97. Harada, H.; Hiraoka, M.; Kizaka-Kondoh, S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res., 2002, 62(7), 2013-2018.
98. Selivanova, G.; Iotsova, V.; Okan, I.; Fritsche, M.; Strom, M.; Groner, B.; Grafstrom, R.C.; Wiman, K.G. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med., 1997, 3(6), 632-638.
99. Phelan, A.; Elliott, G.; O'Hare, P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol, 1998, 16(5), 440-443.
100. Snyder, E.L.; Meade, B.R.; Saenz, C.C.; Dowdy, S.F. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol., 2004, 2(2), E36.
101. Mori, S.; Ito, G.; Usami, N.; Yoshioka, H.; Ueda, Y.; Kodama, Y.; Takahashi, M.; Fong, K.M.; Shimokata, K.; Sekido, Y. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer, 2004, 100(8), 1673-1682.
102. Berger, A.J.; Camp, R.L.; Divito, K.A.; Kluger, H.M.; Halaban, R.; Rimm, D.L. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res., 2004, 64(23), 8767-8772.
103. Harbour, J.W.; Worley, L.; Ma, D.; Cohen, M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol., 2002, 120(10), 1341-1346.
104. Zender, L.; Kock, R.; Eckhard, M.; Frericks, B.; Gosling, T.; Gebhardt, T.; Drobek, S.; Galanski, M.; Kuhnel, F.; Manns, M.; Kubicka, S. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology, 2002, 123(2), 608-618.
105. Takenobu, T.; Tomizawa, K.; Matsushita, M.; Li, S.T.; Moriwaki, A.; Lu, Y.F.; Matsui, H. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol. Cancer Ther., 2002, 1(12), 1043-1049.
106. Gross, A.; McDonnell, J.M.; Korsmeyer, S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev., 1999, 13(15), 1899-1911.
107. Lutz, R.J. Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. Biochem. Soc. Trans., 2000, 28(2), 51-56.
108. Holinger, E.P.; Chittenden, T.; Lutz, R.J. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem., 1999, 274(19), 13298-13304.
109. Letai, A.; Bassik, M.C.; Walensky, L.D.; Sorcinelli, M.D.; Weiler, S.; Korsmeyer, S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2002, 2(3), 183-192.
110. Balkwill, F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol., 2004, 14(3), 171-179.
111. Snyder, E.L.; Saenz, C.C.; Denicourt, C.; Meade, B.R.; Cui, X.S.; Kaplan, I.M.; Dowdy, S.F. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res., 2005, 65(23), 10646-10650.
112. Liu, Y.; Li, Y.; Wang, H.; Yu, J.; Lin, H.; Xu, D.; Wang, Y.; Liang, A.; Liang, X.; Zhang, X.; Fu, M.; Qian, H.; Lin, C. BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer. Mol. Ther., 2009, 17(9), 1509-1516.
113. Martinez-Ruiz, G.; Maldonado, V.; Ceballos-Cancino, G.; Grajeda, J.P.; Melendez-Zajgla, J. Role of Smac/DIABLO in cancer progression. J. Exp. Clin. Cancer Res., 2008, 27, 48.
114. Nachmias, B.; Ashhab, Y.; Ben-Yehuda, D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin. Cancer Biol., 2004, 14(4), 231-243.
115. Deveraux, Q.L.; Takahashi, R.; Salvesen, G.S.; Reed, J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 1997, 388(6639), 300-304.
116. Roy, N.; Deveraux, Q.L.; Takahashi, R.; Salvesen, G.S.; Reed, J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J., 1997, 16(23), 6914-6925.
117. Fulda, S.; Wick, W.; Weller, M.; Debatin, K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med., 2002, 8(8), 808-815.
118. Wu, G.; Chai, J.; Suber, T.L.; Wu, J.W.; Du, C.; Wang, X.; Shi, Y. Structural basis of IAP recognition by Smac/DIABLO. Nature, 2000, 408(6815), 1008-1012.
119. Chai, J.; Du, C.; Wu, J.W.; Kyin, S.; Wang, X.; Shi, Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature, 2000, 406(6798), 855-862.
120. Yang, L.; Mashima, T.; Sato, S.; Mochizuki, M.; Sakamoto, H.; Yamori, T.; Oh-Hara, T.; Tsuruo, T. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginineconjugated Smac peptide. Cancer Res., 2003, 63(4), 831-837.
121. Mizukawa, K.; Kawamura, A.; Sasayama, T.; Tanaka, K.; Kamei, M.; Sasaki, M.; Kohmura, E., Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines. J. Neurooncol., 2006, 77(3), 247-255.
122. Beerens, A.M.; Al Hadithy, A.F.; Rots, M.G.; Haisma, H.J. Protein transduction domains and their utility in gene therapy. Curr. Gene. Ther., 2003, 3(5), 486-494.
123. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411(6836), 494-498.
124. McManus, M.T.; Sharp, P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet., 2002, 3(10), 737-747.
125. Endoh, T.; Ohtsuki, T. Cellular siRNA delivery using cellpenetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev., 2009, 61(9), 704-709.
126. Choi, Y.S.; Lee, J.Y.; Suh, J.S.; Kwon, Y.M.; Lee, S.J.; Chung, J.K.; Lee, D.S.; Yang, V.C.; Chung, C.P.; Park, Y.J. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials, 2010, 31(6), 1429-1443.
127. Crombez, L.; Charnet, A.; Morris, M.C.; Aldrian-Herrada, G.; Heitz, F.; Divita, G. A non-covalent peptide-based strategy for siRNA delivery. Biochem. Soc. Trans., 2007, 35(Pt 1), 44-46.
128. Zhang, C.; Tang, N.; Liu, X.; Liang, W.; Xu, W.; Torchilin, V.P. Sirna-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control Release, 2006, 112(2), 229-239.
129. de Duve, C.; de Barsy, T.; Poole, B.; Trouet, A.; Tulkens, P.; Van Hoof, F. Commentary. Lysosomotropic agents. Biochem. Pharmacol., 1974, 23(18), 2495-2531.
130. Nori, A.; Kopecek, J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev., 2005, 57(4), 609-636.
131. Marcucci, F.; Lefoulon, F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today, 2004, 9(5), 219-228.
132. Kopecek, J.; Kopeckova, P.; Minko, T.; Lu, Z. HPMA copolymeranticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm., 2000, 50(1), 61-81.
133. Moon, C.; Kwon, Y.M.; Lee, W.K.; Park, Y.J.; Chang, L.C.; Yang, V.C. A novel polyrotaxane-based intracellular delivery system for camptothecin: in vitro feasibility evaluation. J. Biomed. Mater Res. A., 2008, 84(1), 238-246.
134. Kwon, Y.M.; Li, Y.; Naik, S.; Liang, J.F.; Huang, Y.; Park, Y.J.; Yang, V.C. The ATTEMPTS delivery systems for macromolecular drugs. Expert Opin. Drug Deliv., 2008, 5(11), 1255-1266.
135. Russell-Jones, G.J.; Alpers, D.H. Vitamin B12 transporters. Pharm. Biotechnol., 1999, 12, 493-520.
136. Greenwald, R.B.; Conover, C.D.; Choe, Y.H. Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. Crit. Rev. Ther. Drug Carrier Syst., 2000, 17(2), 101-161.
137. Liang, J.F.; Park, Y.J.; Song, H.; Li, Y.T.; Yang, V.C. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs. J. Control Release, 2001, 72(1-3), 145-156.
138. Jiang, T.; Olson, E.S.; Nguyen, Q.T.; Roy, M.; Jennings, P.A.; Tsien, R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad Sci. U S A., 2004, 101(51), 17867-17872.
139. Olson, E.S.; Aguilera, T.A.; Jiang, T.; Ellies, L.G.; Nguyen, Q.T.; Wong, E.H.; Gross, L.A.; Tsien, R.Y. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol. (Camb.), 2009, 1(5-6), 382-393.
140. Talvensaari-Mattila, A.; Paakko, P.; Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer, 2003, 89(7), 1270-1275.
141. Kwon, Y.M.; Li, Y.T.; Liang, J.F.; Park, Y.J.; Chang, L.C.; Yang, V.C. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J. Control Release, 2008, 130(3), 252-258.
142. Pujals, S.; Fernandez-Carneado, J.; Lopez-Iglesias, C.; Kogan, M.J.; Giralt, E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim. Biophys. Acta, 2006, 1758(3), 264-279.
143. Choi, S.W.; Lee, S.H.; Mok, H.; Park, T.G. Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide. Biotechnol. Prog., 2010, 26(1), 57-63.
144. Rittner, K.; Benavente, A.; Bompard-Sorlet, A.; Heitz, F.; Divita, G.; Brasseur, R.; Jacobs, E. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol. Ther., 2002, 5(2), 104-114.
145. Elmquist, A.; Hansen, M.; Langel, U. Structure-activity relationship study of the cell-penetrating peptide pVEC. Biochim. Biophys. Acta, 2006, 1758(6), 721-729.